Literature DB >> 33176171

The emerging landscape of nanotheranostic-based diagnosis and therapy for osteoarthritis.

Shuyi Xiao1, Liang Chen2.   

Abstract

Osteoarthritis (OA) is a common degenerative disease involving numerous joint tissues and cells, with a growing rate in prevalence that ultimately results in a negative social impact. Early diagnosis, OA progression monitoring and effective treatment are of significant importance in halting OA process. However, traditional imaging techniques lack sensitivity and specificity, which lead to a delay in timely clinical intervention. Additionally, current treatments only slow the progression of OA but have not meet the largely medical need for disease-modifying therapy. In order to overcome the above-mentioned problems and improve clinical efficacy, nanotheranostics has been proposed on OA remedy, which has confirmed success in animal models. In this review, different imaging targets-based nanoprobe for early and timely OA diagnosis is first discussed. Second, therapeutic strategies delivered by nanosystem are summarized as much as possible. Their advantages and the potential for clinical translation are detailed discussed. Third, nanomedicine simultaneously combined with the imaging for OA treatment is introduced. Nanotheranostics dynamically tracked the OA treatment outcomes to timely and individually adjust therapy. Finally, future prospects and challenges of nanotechnology-based OA diagnosis, imaging and treatment are concluded and predicted. It is believed that nanoprobe and nanomedicine will become prospective in OA therapeutic revolution.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Nanomedicine; Nanoprobe; Osteoarthritis; Theranostic

Year:  2020        PMID: 33176171     DOI: 10.1016/j.jconrel.2020.11.007

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  1 in total

1.  Mesenchymal stem cell-derived extracellular vesicles prevent the development of osteoarthritis via the circHIPK3/miR-124-3p/MYH9 axis.

Authors:  Shenglong Li; Jie Liu; Siyu Liu; Weijie Jiao; Xiaohong Wang
Journal:  J Nanobiotechnology       Date:  2021-06-30       Impact factor: 10.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.